K7PPA8 (K7PPA8_HUMAN) Homo sapiens (Human)
Cellular tumor antigen p53 UniProtKBInterProInteractive Modelling
393 aa; Sequence (Fasta) ;
4 identical sequences: Homo sapiens: P04637; Pan troglodytes: A0A6D2Y7Y2, H2QC53; Pan paniscus: A0A2R9A5P4
Available Structures
272 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Structure of the p53/RNA polymerase II assembly |
Heteromer O15514; P04637; P19387; P19388; P24928; P30876; P36954; P52434; P52435; P53803; P61218; P62487; P62875; | 1×MG; 8×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of p300-p53 protein complex |
Heteromer P04637; Q09472; | |||||
| Assess | ||||||
| Dimeric ternary structure of E6AP-E6-p53 |
Heteromer P03126; P04637; Q05086; | 6×ZN; | ||||
| Assess | ||||||
| Monomeric E6AP-E6-p53 ternary complex |
Heteromer P03126; P04637; Q05086; | 3×ZN; | ||||
| Assess | ||||||
| Crystal structure of a complex between the DNA-binding domain of p53 and the carboxyl-terminal cons… |
Heteromer P04637; Q8WUF5; | 1×ZN; | ||||
| Assess | ||||||
| p53 DNA binding domain in complex with Nb139 |
Heteromer P04637; | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of the HPV16 E6/E6AP/p53 ternary complex at 2.25 A resolution |
Heteromer P03126; P04637; P0AEX9; Q05086; | 1×GLC; 2×PEG; 3×ZN; 1×EDO; | ||||
| Assess | ||||||
| The crystal structure of p53 DNA binding domain and PUMA complex |
Heteromer P04637; Q9BXH1; | 4×ZN; | ||||
| Assess | ||||||
| Crystal structure of p53 DBD domain in complex with azurin |
Heteromer P00282; P04637; | 2×NA; 2×ZN; 2×K; 1×PO4; | ||||
| Assess | ||||||
| Crystal structure of the BRCT domains of human 53BP1 bound to the p53 tumor supressor |
Heteromer P04637; Q12888; | 1×ZN; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of the BRCT domains of 53BP1 in complex with p53 and H2AX-pSer139 (gammaH2AX) |
Heteromer P04637; Q12888; | 1×ZN; | ||||
| Assess | ||||||
| The Structure of the Oncoprotein SV40 Large T Antigen and p53 Tumor Suppressor Complex |
Heteromer P03070; P04637; | 12×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of the nucleosome in complex with p53 DNA-binding domain |
Heteromer P04637; P04908; P06899; P62805; P68431; | |||||
| Assess | ||||||
| Cryo-EM structure of the nucleosome in complex with p53 |
Heteromer P04637; P04908; P06899; P62805; P68431; | |||||
| Assess | ||||||
| Crystal Structure of the 53bp1 BRCT Region Complexed to Tumor Suppressor P53 |
Heteromer P04637; Q12888; | 2×ZN; | ||||
| Assess | ||||||
| Solution Structure of the Complex Between BCL-xL and the p53 Core Domain determined with PRE restra… |
Heteromer P04637; Q07817; | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of p53/BCL2 fusion complex(complex3) |
Heteromer P04637; P10415; | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of p53/BCL2 fusion complex (complex 2) |
Heteromer P04637; P10415; | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of p53/BCL2 fusion complex (complex 1) |
Heteromer P04637; P10415; | 1×ZN; | ||||
| Assess | ||||||
| HPV16 E6-E6AP-p53 complex |
Heteromer P03126; P04637; Q05086; | 3×ZN; | ||||
| Assess | ||||||
| P53-53BP2 COMPLEX |
Heteromer P04637; Q13625; | 1×ZN; | ||||
| Assess | ||||||
| Structure of CBP nuclear coactivator binding domain in complex with p53 TAD |
Heteromer P04637; P45481; | |||||
| Assess | ||||||
| HMGB1-facilitated p53 DNA binding occurs via HMG-box/p53 transactivation domain interaction and is … |
Heteromer P04637; P09429; | |||||
| Assess | ||||||
| Structural Basis for the Regulation of p53 Function by p300 |
Heteromer P04637; Q09472; | |||||
| Assess | ||||||
| Transactivation domain of p53 in complex with S100P, using annexin A2 as crystallization chaperone |
Heteromer P04637; P07355; P25815; | 1×GOL; 9×CA; | ||||
| Assess | ||||||
| Crystal Structure of a Designed Protein Heterocatenane |
Heteromer P04637; P42212; | |||||
| Assess | ||||||
| Characterization of the p300 Taz2-p53 TAD2 Complex and Comparison with the p300 Taz2-p53 TAD1 Compl… |
Heteromer P04637; Q09472; | |||||
| Assess | ||||||
| p53N (fragment 33-60) bound to RPA70N |
Heteromer P04637; P27694; | |||||
| Assess | ||||||
| Solution structure of the complex between p53 transactivation domain 2 and TFIIH p62 PH domain |
Heteromer P04637; P32780; | |||||
| Assess | ||||||
| NMR Structure of CBP Bromodomain in complex with p53 peptide |
Heteromer P04637; Q92793; | |||||
| Assess | ||||||
| Solution structure of 53BP1 tandem Tudor domains in complex with a p53K370me2 peptide |
Heteromer P04637; Q12888; | |||||
| Assess | ||||||
| Mdmx-p53 |
Heteromer O15151; P04637; | |||||
| Assess | ||||||
| Crystal Structure Analysis of Zebra Fish MDMX |
Heteromer P04637; Q7ZUW7; | 1×SO4; | ||||
| Assess | ||||||
| Crystal Structure Analysis of Zebra Fish MDMX |
Heteromer P04637; Q7ZUW7; | |||||
| Assess | ||||||
| NMR structure of the complex between the PH domain of the Tfb1 subunit from TFIIH and the activatio… |
Heteromer P04637; P32776; | |||||
| Assess | ||||||
| Sir2-p53 peptide-nicotinamide |
Heteromer P04637; Q9WYW0; | 1×ZN; 1×NCA; | ||||
| Assess | ||||||
| The Structural Basis for Sirtuin Substrate Affinity |
Heteromer P04637; Q9WYW0; | 1×ZN; | ||||
| Assess | ||||||
| Structure of Sir2Tm bound to a propionylated peptide |
Heteromer P04637; Q9WYW0; | 1×ZN; | ||||
| Assess | ||||||
| MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 |
Heteromer P04637; Q00987; | |||||
| Assess | ||||||
| Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide |
Heteromer P04637; P31947; | 2×CA; 2×MG; | ||||
| Assess | ||||||
| Fragment AZ-003 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 4×MG; 2×CL; 2×GOL; 2×K48; | ||||
| Assess | ||||||
| Fragment AZ-010 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 2×KM8; | ||||
| Assess | ||||||
| Fragment AZ-009 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 2×KLZ; 2×MG; | ||||
| Assess | ||||||
| Fragment AZ-015 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 4×MG; 2×CL; 2×GOL; 2×K6B; | ||||
| Assess | ||||||
| Fragment AZ-026 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 4×MG; 2×CL; 2×K92; | ||||
| Assess | ||||||
| Fragment AZ-025 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 4×MG; 2×CL; 2×K7N; | ||||
| Assess | ||||||
| Fragment AZ-024 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 2×MG; 2×CL; 2×K7Q; | ||||
| Assess | ||||||
| Fragment AZ-011 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 4×MG; 2×CL; 2×LFB; | ||||
| Assess | ||||||
| Fragment AZ-017 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 4×MG; 2×CL; 4×LFQ; | ||||
| Assess | ||||||
| Fragment AZ-020 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 2×K65; | ||||
| Assess | ||||||
| Fragment AZ-002 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 2×KLE; 2×CA; 4×MG; | ||||
| Assess | ||||||
| Fragment AZ-007 binding at a primary and secondary binding site of the the p53pT387/14-3-3 sigma co… |
Heteromer P04637; P31947; | 4×KLB; 2×CA; 4×MG; | ||||
| Assess | ||||||
| Fragment AZ-004 binding at a primary and secondary site in a p53pT387/14-3-3 complex |
Heteromer P04637; P31947; | 6×L1T; 2×CA; | ||||
| Assess | ||||||
| Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide |
Heteromer P04637; P31947; | 2×CL; 2×MG; | ||||
| Assess | ||||||
| Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain |
Heteromer P04637; Q7ZUW7; | |||||
| Assess | ||||||
| Fragment AZ-018 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 2×K5Z; 2×CA; | ||||
| Assess | ||||||
| Fragment AZ-022 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 2×MG; 2×CL; 2×GOL; 4×K6Z; | ||||
| Assess | ||||||
| Fragment AZ-023 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 4×MG; 2×CL; 2×K6T; | ||||
| Assess | ||||||
| Fragment AZ-013 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 6×MG; 2×CL; 2×LJW; | ||||
| Assess | ||||||
| Fragment AZ-001 binding at the p53pT387/14-3-3 sigma interface and additional sites |
Heteromer P04637; P31947; | 8×MG; 2×CL; 8×KTW; 2×GOL; 2×CA; | ||||
| Assess | ||||||
| Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain |
Heteromer O15151; P04637; | |||||
| Assess | ||||||
| Solution structure of 53BP1 tandem Tudor domains in complex with a p53K382me2 peptide |
Heteromer P04637; Q12888; | |||||
| Assess | ||||||
| Sir2-deacetylated peptide (from enzymatic turnover in crystal) |
Heteromer P04637; Q9WYW0; | 1×ZN; 1×NCA; 1×OAD; | ||||
| Assess | ||||||
| Molecular basis for the inhibition of p53 by Mdmx |
Heteromer P04637; Q7ZUW7; | |||||
| Assess | ||||||
| XENOPUS LAEVIS MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF HUMAN P53 |
Heteromer P04637; P56273; | |||||
| Assess | ||||||
| Molecular basis for the inhibition of p53 by Mdmx |
Heteromer P04637; Q7ZUW7; | |||||
| Assess | ||||||
| Crystal Structure of an MDM2/P53 Peptide Complex |
Heteromer P04637; Q00987; | 1×SO4; | ||||
| Assess | ||||||
| Fragment AZ-012 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 2×CL; 4×LF5; | ||||
| Assess | ||||||
| Crystal structure of the 53BP1 tandem tudor domain in complex with p53K381acK382me2 |
Heteromer P04637; Q12888; | |||||
| Assess | ||||||
| Fragment AZ-021 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 4×MG; 2×CL; 2×GOL; 2×K6W; | ||||
| Assess | ||||||
| Fragment AZ-006 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 4×MG; 2×CL; 2×GOL; 2×JT2; | ||||
| Assess | ||||||
| Fragment AZ-019 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 2×MG; 2×CL; 2×GOL; 2×KDK; | ||||
| Assess | ||||||
| Structure of a Sir2 enzyme bound to an acetylated p53 peptide |
Heteromer O30124; P04637; | 1×ZN; 1×MES; | ||||
| Assess | ||||||
| Crystal Structure of human O-GlcNAcase in complex with glycopeptide p53 |
Heteromer O60502; P04637; | 2×NAG; | ||||
| Assess | ||||||
| CDK2/CyclinA in complex with an 11-residue recruitment peptide from p53 |
Heteromer P04637; P20248; P24941; | |||||
| Assess | ||||||
| Complex of HLA-A2, a class I MHC, with a p53 peptide |
Heteromer A0A140T913; P04637; P61769; | |||||
| Assess | ||||||
| Complex of HLA-A2, a class I MHC, with a p53 peptide |
Heteromer A0A140T913; P04637; P61769; | |||||
| Assess | ||||||
| T cell receptor-p53-HLA-A2 complex |
Heteromer A0A140T913; P04637; P61769; | |||||
| Assess | ||||||
| T cell receptor-p53-HLA-A2 complex |
Heteromer A0A140T913; P04637; P61769; | |||||
| Assess | ||||||
| T cell receptor-p53-HLA-A2 complex |
Heteromer A0A140T913; P04637; P61769; | |||||
| Assess | ||||||
| Neoantigen p53R175H-specific TCR 6-11 binds to p53R175H-HLA-A2 |
Heteromer P04439; P04637; P61769; | |||||
| Assess | ||||||
| Structure of the antibody fragment H2 in complex with HLA-A*02:01/p53R175H |
Heteromer A0A140T913; P04637; P61769; | |||||
| Assess | ||||||
| Fragment AZ-014 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 4×MG; 2×CL; 2×K6N; | ||||
| Assess | ||||||
| Fragment AZ-016 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 6×MG; 2×CL; 4×K8W; | ||||
| Assess | ||||||
| Structure of Leishmania infantum Silent Information Regulator 2 related protein 1 (LiSIR2rp1) in co… |
Heteromer A0A6L0XH39; P04637; | 1×ZN; | ||||
| Assess | ||||||
| Sir2 H116Y mutant-p53 peptide-NAD |
Heteromer P04637; Q9WYW0; | 1×ZN; 1×NAD; | ||||
| Assess | ||||||
| Sir2-p53 peptide-NAD+ |
Heteromer P04637; Q9WYW0; | 1×ZN; 1×NAD; | ||||
| Assess | ||||||
| Structure of SMYD2 in complex with p53 and SAH |
Heteromer P04637; Q9NRG4; | 1×GOL; 1×SAH; 3×ZN; | ||||
| Assess | ||||||
| CpOGA D298N in complex with p53-derived O-GlcNAc peptide |
Heteromer P04637; Q0TR53; | 18×CD; 1×NAG; | ||||
| Assess | ||||||
| Binary complex of 14-3-3 sigma and p53 pT387-peptide |
Heteromer P04637; P31947; | 6×MG; 2×CL; 2×GOL; | ||||
| Assess | ||||||
| The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with p53 peptide 364-367 |
Heteromer P04637; Q93009; | |||||
| Assess | ||||||
| Fragment AZ-005 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 6×MG; 2×CA; 2×KM2; | ||||
| Assess | ||||||
| SIR2 COMPLEX STRUCTURE MIXTURE OF EX-527 INHIBITOR AND REACTION PRODUCTS OR OF REACTION SUBSTRATES … |
Heteromer P04637; Q9WYW0; | 1×OCZ; 1×NAD; 1×OAD; 1×ZN; 1×EDO; | ||||
| Assess | ||||||
| The Structural basis for Sirtuin Substrate affinity |
Heteromer P04637; Q9WYW0; | 1×ZN; | ||||
| Assess | ||||||
| SIRT1/Activator/Substrate Complex |
Heteromer P04637; Q96EB6; | 1×ZN; 1×CNA; 1×4TQ; 2×GOL; | ||||
| Assess | ||||||
| ATM(Q2971A) dimeric C-terminal region activated by oxidative stress in complex with Mg AMP-PNP and … |
Heteromer P04637; Q13315; | 2×ANP; 2×MG; 2×ZN; | ||||
| Assess | ||||||
| ATM(Q2971A) activated by oxidative stress in complex with Mg AMP-PNP and p53 peptide |
Heteromer P04637; Q13315; | 2×ANP; 2×MG; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of a ternary complex of the methyltransferase SET9 (also known as SET7/9) with a … |
Heteromer P04637; Q8WTS6; | 1×SAH; | ||||
| Assess | ||||||
| Sir2 H116A-deacetylated p53 peptide-3'-o-acetyl ADP ribose |
Heteromer P04637; Q9WYW0; | 2×ZN; 1×APR; 1×3OD; | ||||
| Assess | ||||||
| The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with p53 peptide 359-362 |
Heteromer P04637; Q93009; | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF SIR2 IN COMPLEX WITH THE INHIBITOR EX-527, 2'-O-ACETYL-ADP-RIBOSE AND DEACETYL… |
Heteromer P04637; Q9WYW0; | 1×OCZ; 1×OAD; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of HDAC8-substrate complex |
Heteromer P04637; Q9BY41; | 2×K; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of SIRT3 in complex with acetyl p53 peptide coupled with 4-amino-7-methylcoumarin |
Heteromer P04637; Q9NTG7; | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of the 3-MBT domain from human L3MBTL1 in complex with p53K382me1 |
Heteromer P04637; Q9Y468; | |||||
| Assess | ||||||
| Structure of the amyloid-forming segment LTIITLE from p53 (residues 252-258) | homo-6-mer | |||||
| Assess | ||||||
| Structure of the amyloid-forming segment TIITLE from p53 (residues 253-258) | homo-6-mer | 6×ZN; | ||||
| Assess | ||||||
| An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| Crystal structure of a multidomain human p53 tetramer bound to the natural CDKN1A(p21) p53-response… | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| Crystal structure of a polypeptide p53 mutant bound to DNA | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-4-mer | 4×ZN; 4×QN8; 4×QNN; 48×FMT; 4×ACT; 8×EDO; | ||||
| Assess | ||||||
| New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LHG1) | homo-4-mer | 4×ZN; 12×EDO; 4×FOR; | ||||
| Assess | ||||||
| New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-p53R2) | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-GADD45) | homo-4-mer | 4×ZN; 2×PEG; | ||||
| Assess | ||||||
| New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LWC1) | homo-4-mer | 4×ZN; 20×EDO; 4×ACT; | ||||
| Assess | ||||||
| Structural Basis of DNA Recognition by p53 Tetramers (complex I) | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| Structural Basis of DNA Recognition by p53 Tetramers (complex III) | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-4-mer | 4×ZN; 4×FMT; | ||||
| Assess | ||||||
| Crystal structure of p53 core domain in complex with DNA | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R273C and second-site suppressor mutation T284R in seq… | homo-4-mer | 4×ZN; 16×EDO; 2×ACT; | ||||
| Assess | ||||||
| New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LWC2) | homo-4-mer | 4×ZN; 4×FOR; | ||||
| Assess | ||||||
| New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-AGG-HG) | homo-4-mer | 4×ZN; 14×EDO; | ||||
| Assess | ||||||
| Structural Basis of DNA Recognition by p53 Tetramers (complex II) | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| Structural Basis of DNA Recognition by p53 Tetramers (complex IV) | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs (p53-D… | homo-4-mer | 4×ZN; 4×IOD; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R282W in complex with the natural CDKN1A(p21) p53-resp… | homo-4-mer | 4×ARS; 4×ZN; | ||||
| Assess | ||||||
| Lysine 120-acetylated P53 DNA binding domain in a complex with the BAX response element. | homo-4-mer | 4×ZN; | ||||
| Assess | ||||||
| New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LHG2) | homo-4-mer | 4×ZN; 12×EDO; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-4-mer | 4×ZN; 7×QN8; 1×ACT; 1×QNN; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-4-mer | 4×ZN; 6×QNN; 4×EDO; 1×QN8; 2×PEG; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-4-mer | 4×ZN; 2×QNN; 6×EDO; 2×ACT; 3×PEG; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-4-mer | 4×ZN; 4×QN8; 6×QNN; 4×EDO; 2×PEG; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-4-mer | 4×ZN; 6×QN8; 4×QNN; | ||||
| Assess | ||||||
| HIGH-RESOLUTION SOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMR | homo-4-mer | |||||
| Assess | ||||||
| HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NM… | homo-4-mer | |||||
| Assess | ||||||
| HIGH-RESOLUTION SOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMR | homo-4-mer | |||||
| Assess | ||||||
| HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NM… | homo-4-mer | |||||
| Assess | ||||||
| HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NM… | homo-4-mer | |||||
| Assess | ||||||
| HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NM… | homo-4-mer | |||||
| Assess | ||||||
| HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NM… | homo-4-mer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF P53 TETRAMERIZATION DOMAIN | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of the human p53 tetramerization domain | homo-4-mer | |||||
| Assess | ||||||
| P53 TETRAMERIZATION DOMAIN CRYSTAL STRUCTURE | homo-4-mer | |||||
| Assess | ||||||
| NMR SOLUTION STRUCTURE OF THE TETRAMERIC MINIMUM TRANSFORMING DOMAIN OF P53 | homo-4-mer | |||||
| Assess | ||||||
| p53 tetramerization domain wild type | homo-4-mer | |||||
| Assess | ||||||
| p53 tetramerization domain mutant T329F Q331K | homo-4-mer | |||||
| Assess | ||||||
| NMR SOLUTION STRUCTURE OF THE TETRAMERIC MINIMUM TRANSFORMING DOMAIN OF P53 | homo-4-mer | |||||
| Assess | ||||||
| p53 tetramerization domain mutant Y327S T329G Q331G | homo-4-mer | |||||
| Assess | ||||||
| P53 CORE DOMAIN IN COMPLEX WITH DNA | homo-3-mer | 3×ZN; | ||||
| Assess | ||||||
| TUMOR SUPPRESSOR P53 COMPLEXED WITH DNA | homo-3-mer | 3×ZN; | ||||
| Assess | ||||||
| Wild type P53 dimer structure from human cancer cells | homo-2-mer | |||||
| Assess | ||||||
| An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity | homo-2-mer | 2×ZN; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-2-mer | 2×ZN; 4×QN8; 2×QNN; 4×FMT; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-2-mer | 2×ZN; 2×ACT; 2×EDO; 4×QN8; 2×QNN; 8×FMT; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-2-mer | 2×ZN; 6×QN8; 2×QNN; 2×PG4; 4×EDO; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-2-mer | 2×ZN; 6×QNN; 2×QN8; | ||||
| Assess | ||||||
| Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs (p53-D… | homo-2-mer | 2×ZN; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-2-mer | 2×ZN; 4×FMT; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R273H and second-site suppressor mutation T284R in seq… | homo-2-mer | 2×ZN; 34×EDO; | ||||
| Assess | ||||||
| Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs (p53-D… | homo-2-mer | 2×ZN; 2×EDO; | ||||
| Assess | ||||||
| Lysine 120-acetylated P53 DNA binding domain in a complex with DNA. | homo-2-mer | 2×ZN; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-2-mer | 2×ZN; 6×QNN; 2×QN8; 6×FMT; | ||||
| Assess | ||||||
| Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi… | homo-2-mer | 2×ZN; 8×EDO; 2×PEG; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R273C and second-site suppressor mutation S240R in seq… | homo-2-mer | 14×EDO; 2×ZN; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R249S and second site suppressor mutation H168R in seq… | homo-2-mer | 2×ZN; | ||||
| Assess | ||||||
| NMR SOLUTION STRUCTURE OF DESIGNED P53 DIMER | homo-2-mer | |||||
| Assess | ||||||
| SOLUTION STRUCTURE DETERMINATION OF A P53 MUTANT DIMERIZATION DOMAIN, NMR, MINIMIZED AVERAGE STRUCT… | homo-2-mer | |||||
| Assess | ||||||
| P53 monomer structure | monomer | |||||
| Assess | ||||||
| p53 charged core | monomer | 2×GOL; 1×ZN; | ||||
| Assess | ||||||
| Solution structure of human p53 DNA binding domain. | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain with germline hot spot mutation M133T in complex with the natural PIG3 p53-re… | monomer | 1×ARS; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of p53DBD(R282Q) at 1.54-angstrom Resolution | monomer | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of the DNA-binding domain of human p53 with extended N terminus | monomer | 1×ZN; | ||||
| Assess | ||||||
| The Crystal Structure of p53 from Biortus. | monomer | 1×PO4; 1×ZN; 1×EDO; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9318 | monomer | 1×ZN; 1×EXQ; 1×EDO; | ||||
| Assess | ||||||
| p53-Y220C Core Domain in Complex with a Bromo-trifluoro-pyrazole-amine | monomer | 1×LE9; 1×EPE; 1×ZN; 1×PEG; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R273H (form II) | monomer | 2×ZN; 1×DTT; 3×EDO; | ||||
| Assess | ||||||
| Human p53 Core Domain Mutant V157F/N235K/N239Y | monomer | 1×ZN; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9320 | monomer | 1×ZN; 1×EXN; 2×EDO; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C | monomer | 2×EDO; 1×ZN; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9327 | monomer | 1×ZN; 1×EYE; | ||||
| Assess | ||||||
| Crystal structure of the p53 (Y107H) core domain orthorhombic P form | monomer | 1×ZN; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C im complex with compound MB577 | monomer | 1×ZN; 1×9GT; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with compound MB184 | monomer | 1×ZN; 1×9GZ; | ||||
| Assess | ||||||
| Crystal structure of the p53 cancer mutant Y220C in complex with a difluorinated derivative of the … | monomer | 1×ZN; 1×O83; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with compound MB481 | monomer | 1×ZN; 1×9GW; | ||||
| Assess | ||||||
| p53 cancer mutant Y220S in complex with small-molecule stabilizer PK9301 | monomer | 1×ZN; 1×LEB; 2×EDO; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with compound MB84 | monomer | 1×ZN; 1×9H2; 2×GOL; | ||||
| Assess | ||||||
| p53 cancer mutant Y220H | monomer | 1×ZN; 1×EDO; 1×GOL; 1×EPE; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R273H and second-site suppressor mutation S240R | monomer | 1×ZN; 2×EDO; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with iodophenol-based small-molecule stabilizer JC694 | monomer | 1×KV0; 1×ZN; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with iodophenol-based small-molecule stabilizer JC769 | monomer | 1×KVA; 1×EDO; 1×ZN; | ||||
| Assess | ||||||
| Structure of the p53 cancer mutant Y220C with bound 3-bromo-5-(trifluoromethyl)benzene-1,2-diamine | monomer | 1×UFV; 1×ZN; | ||||
| Assess | ||||||
| Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5086 | monomer | 1×P86; 1×ZN; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9323 | monomer | 1×ZN; 1×LEK; 1×EDO; | ||||
| Assess | ||||||
| Structure of p53 cancer mutant Y220C with arylation at Cys182 and Cys277 | monomer | 1×ZN; | ||||
| Assess | ||||||
| Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5116 | monomer | 1×ZN; 1×NXG; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with compound MB539 | monomer | 1×ZN; 1×9GN; | ||||
| Assess | ||||||
| Structure of the p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9328 | monomer | 1×ZN; 1×EXQ; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with compound MB487 | monomer | 1×ZN; 1×9GK; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with compound MB582 | monomer | 1×ZN; 1×9GQ; | ||||
| Assess | ||||||
| Structure of the p53 cancer Y220C bound to the stabilizing small molecule PhiKan5211 | monomer | 1×ZN; 1×KMN; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with compound MB710 | monomer | 1×ZN; 1×9GH; 1×EDO; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9324 | monomer | 1×ZN; 1×EYB; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with compound MB240 | monomer | 1×ZN; 1×9H5; | ||||
| Assess | ||||||
| Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5174 | monomer | 1×P74; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of the p53 cancer mutant Y220C in complex with a trifluorinated derivative of the… | monomer | 1×ZN; 1×O80; | ||||
| Assess | ||||||
| Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5176 | monomer | 1×P51; 1×ZN; | ||||
| Assess | ||||||
| p53 cancer mutant Y220S | monomer | 1×ZN; 2×EDO; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9284 | monomer | 1×EY2; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of p53 Y220C covalently bound to indole KG6 | monomer | 1×ZN; 5×SO4; 1×R4F; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R273H and second-site suppressor mutation T284R | monomer | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of p53 Y220C covalently bound to azaindole KG13 | monomer | 1×R50; 2×SO4; 1×ZN; 1×MG; | ||||
| Assess | ||||||
| HUMAN P53 CORE DOMAIN MUTANT M133L-V203A-Y236F-N239Y-T253I-N268D | monomer | 1×ZN; | ||||
| Assess | ||||||
| p53 cancer mutant Y220S in complex with small-molecule stabilizer PK9323 | monomer | 1×ZN; 1×LEK; | ||||
| Assess | ||||||
| Crystal structure of p53 Y220C covalently bound to indole KG10 | monomer | 3×SO4; 1×ZN; 2×MG; 1×R4R; | ||||
| Assess | ||||||
| Crystal structure of p53 Y220C covalently bound to carbazole KG3 | monomer | 1×ZN; 1×R3R; | ||||
| Assess | ||||||
| The Crystal Structure of p53/BCL-xL fusion complex from Biortus. | monomer | 1×ZN; | ||||
| Assess | ||||||
| Structure of the p53 cancer mutant Y220C with bound small molecule PhiKan7099 | monomer | 1×ZN; 1×GOL; 1×GOH; | ||||
| Assess | ||||||
| Structure of the p53 core domain mutant Y220C bound to the small molecule PhiKan7242 | monomer | 1×ZN; 1×QC5; | ||||
| Assess | ||||||
| Structure of the p53 cancer mutant Y220C with bound small molecule 7- ethyl-3-(piperidin-4-yl)-1H-i… | monomer | 1×ZN; 1×PEG; 2×92O; | ||||
| Assess | ||||||
| Crystal structure of the p53 cancer mutant Y220C in complex with a monofluorinated derivative of th… | monomer | 1×ZN; 1×O82; | ||||
| Assess | ||||||
| Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5196 | monomer | 1×P96; 1×ZN; | ||||
| Assess | ||||||
| p53 cancer mutant Y220C with Cys182 alkylation | monomer | 1×ZN; 1×6SM; | ||||
| Assess | ||||||
| Structure of the p53 cancer mutant Y220C in complex with 2-hydroxy-3, 5-diiodo-4-(1H-pyrrol-1-yl)be… | monomer | 1×Y0V; 1×ZN; | ||||
| Assess | ||||||
| Structure of the p53 core domain mutant Y220C bound to the stabilizing small-molecule drug PhiKan083 | monomer | 1×ZN; | ||||
| Assess | ||||||
| STRUCTURE OF THE P53 CORE DOMAIN MUTANT Y220C BOUND TO A 2-amino substituted benzothiazole scaffold | monomer | 1×ZN; | ||||
| Assess | ||||||
| Structure of the p53 cancer mutant Y220C with bound small-molecule stabilizer PhiKan5149 | monomer | 1×ZN; 1×UL7; | ||||
| Assess | ||||||
| Human p53 core domain mutant M133L-V203A-Y220C-N239Y-N268D | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain mutant M133L-V203A-N239Y-G245S-N268D | monomer | 1×ZN; 1×CA; | ||||
| Assess | ||||||
| Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan784 | monomer | 1×P84; 1×ZN; | ||||
| Assess | ||||||
| Structure of the p53 cancer mutant Y220C with bound small molecule PhiKan883 | monomer | 2×FY8; 1×GOL; 1×ZN; | ||||
| Assess | ||||||
| Structure of the p53 cancer mutant Y220C in complex with an indole- based small molecule | monomer | 1×ZN; | ||||
| Assess | ||||||
| human p53 core domain mutant M133L-H168R-V203A-N239Y-R249S-N268D | monomer | 1×ZN; | ||||
| Assess | ||||||
| human p53 core domain mutant T123A-M133L-H168R-V203A-N239Y-R249S- N268D | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain mutant M133L-V143A-V203A-N239Y-N268D | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain mutant M133L-V203A-N239Y-N268D-F270L | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain mutant M133L-V203A-N239Y-N268D-R273C | monomer | 1×ZN; 1×SO4; | ||||
| Assess | ||||||
| STRUCTURE OF THE P53 CORE DOMAIN MUTANT Y220C BOUND TO 4-(trifluoromethyl)benzene-1,2-diamine | monomer | 1×ZN; | ||||
| Assess | ||||||
| human p53 core domain mutant M133L-H168R-V203A-N239Y-N268D | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R249S and second-site suppressor mutations H168R and T… | monomer | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of the human p53 core domain mutant M133L/V203A/N239Y/N268D at 1.9 A resolution. | monomer | 1×ZN; | ||||
| Assess | ||||||
| human p53 core domain mutant M133L-V203A-N239Y-N268D-R273H | monomer | 1×ZN; 1×SO4; | ||||
| Assess | ||||||
| STRUCTURE OF THE P53 CORE DOMAIN MUTANT Y220C BOUND TO 5,6-dimethoxy- 2-methylbenzothiazole | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R249S (III) | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 Core Domain Mutant V157F | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 Core Domain Mutant N239Y | monomer | 1×ZN; | ||||
| Assess | ||||||
| human p53 core domain mutant M133L-V203A-N239Y-R249S-N268D | monomer | 1×ZN; | ||||
| Assess | ||||||
| Arsenic-bound p53 DNA-binding domain mutant V272M | monomer | 1×ARS; 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain in the absence of DNA | monomer | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of p53/BCL-xL fusion complex | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 Core Domain Mutant N235K | monomer | 1×ZN; | ||||
| Assess | ||||||
| Crystal complex of p53-V272M and antimony ion | monomer | 1×ZN; 1×SB; | ||||
| Assess | ||||||
| Crystal structure of a human mutant p53 | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain mutant M133L-V203A-N239Y-N268D-R282W | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R249S (II) | monomer | 1×ZN; | ||||
| Assess | ||||||
| Arsenic-bound p53 DNA-binding domain mutant R249S | monomer | 1×GOL; 1×ARS; 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R273H (form I) | monomer | 1×ZN; | ||||
| Assess | ||||||
| Structure of Lys120-acetylated p53 core domain | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R273C and second-site suppressor mutation T284R | monomer | 1×ZN; 4×EDO; | ||||
| Assess | ||||||
| Mutant R280K of human P53 | monomer | 1×ZN; | ||||
| Assess | ||||||
| Arsenic-bound p53 DNA-binding domain mutant G245S | monomer | 1×ARS; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of the p53 (Y107H) core domain monoclinic P form | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R249S (I) | monomer | 1×ZN; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R273C | monomer | 1×ZN; 1×ACT; | ||||
| Assess | ||||||
| Human p53 core domain with hot spot mutation R249S and second-site suppressor mutation H168R | monomer | 1×ZN; | ||||
| Assess | ||||||
| Solution Structure of p53TAD-TAZ1 | monomer | 3×ZN; | ||||
| Assess | ||||||
| Solution Structure of TAZ2-p53TAD | monomer | 3×ZN; | ||||
| Assess | ||||||
| Structure determination of the transactivation domain of p53 in complex with S100A4 using annexin A… | monomer | 2×GOL; 10×CA; | ||||
| Assess | ||||||
| Solution Structure of TAZ2-p53AD2 | monomer | 3×ZN; | ||||
| Assess | ||||||
| The crystal structure of p53p peptide fragment in complex with the N-terminal domain of MdmX | monomer | 2×O4B; 2×MG; | ||||
| Assess | ||||||
4 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 3q05.1.A | monomer | 0.68 | 1×ZN; | 92.70 | ||
| Assess | ||||||
| 8f2h.1.B | monomer | 0.68 | 100.00 | |||
| Assess | ||||||
| 3q01.1.B | monomer | 0.67 | 1×ZN; | 92.70 | ||
| Assess | ||||||
| 6xre.1.M | monomer | 0.64 | 100.00 | |||
| Assess | ||||||